Skip to content
Nobel Jews
Portrait of Christian Anfinsen
Photo: Hubbard, Edward A.; National Institutes of Health, http://profiles.nlm.nih.gov/KK/B/B/B/G/ · Public domain via Wikimedia Commons

Nobel Prize in Chemistry · 1972

Christian Anfinsen

He showed that a protein's chain of amino acids alone decides its shape, the rule behind today's AI protein-structure prediction.

The Nobel citation: “for his work on ribonuclease, especially concerning the connection between the amino acid sequence and the biologically active conformation”
Born
March 26, 1916, Monessen, PA, USA
Died
May 14, 1995, Randallstown, MD, USA
Shared with
Stanford Moore, William H. Stein
Affiliation at the time
National Institutes of Health, USA

Chemistry prize

1972

Shared with 2 other laureates.

Age that year

56years

Born in 1916.

Headline credited impact

$7.5–10billion in economic value

Cumulative global sales of genetically engineered non-antibody protein medicines (a proxy for economic activity). How it was built

Sources cited

31

Fact-checked September 24, 2026.

  • The enzyme behind his Nobel Prize came from Armour, a Chicago meatpacker with a big supply of cow ribonuclease, probably a by-product of making insulin.
  • Unraveled, the ribonuclease chain could pair its 8 sulfur-bearing links in 105 ways. Left to refold, it found the one correct pairing on its own.
  • He gave his 1972 Nobel banquet thanks in what he called a mix of Scandinavian languages, fitting for the son of Norwegian immigrants.
  • In 1979 he converted to Orthodox Judaism. He chose the Hebrew name Chaim, which his widow said was inspired by Chaim Weizmann.
  • In 1984 he was one of 55 Western scientists who offered to trade places with Yelena Bonner, Andrei Sakharov's wife, so she could go West for medical care.

The breakthrough

A protein's sequence sets its shape: the ribonuclease refolding experiments

Proteins do most of the work in living things. Each one starts as a chain of building blocks called amino acids, strung together in an order set by a gene. To work, the chain must fold into one precise 3D shape. In the 1950s nobody knew where the folding instructions came from. Did the cell need extra machinery or a template to guide it? Anfinsen tested this with ribonuclease, a small enzyme of 124 amino acids that cuts up RNA. Its shape is locked by four bridges between sulfur atoms. Using strong urea and a chemical that breaks those bridges, his team unraveled the chain until it stopped working. Then they took the chemicals away. The chain folded back up by itself and its activity returned. Its eight sulfur-bearing links could have paired up in 105 different ways, yet the chain found the one correct pairing on its own. Think of a length of memory wire that springs back into the same shape every time you straighten it and let go. His conclusion, the 'thermodynamic hypothesis', is that a protein's working shape is its most stable arrangement in the conditions inside a cell. So the amino acid sequence alone holds everything needed to reach it. Because refolding in a test tube took far longer than in a living cell, his lab went looking for help and found an enzyme that speeds up the pairing of sulfur bridges.[1],[3],[4],[6],[9],[20]

“the native conformation is determined by the totality of interatomic interactions and hence by the amino acid sequence, in a given environment.”
Christian Anfinsen, Stating his 'thermodynamic hypothesis' in his Nobel lecture, 11 December 1972: a protein's working shape is set by its chain of amino acids and its surroundings.[3]

What it meant for humanity

Anfinsen's rule is now so basic to biology that it is easy to forget it was once doubted. It changed lives mostly through what others built on it. First, it set one of science's great puzzles: if the sequence decides the shape, the shape should be predictable from the sequence. Scientists worked on that problem for more than half a century. In 2024 half of the Nobel Prize in Chemistry went to the creators of AlphaFold, an AI system that has predicted the structures of nearly all 200 million known proteins, and the Nobel committee's account traces the challenge back to Anfinsen's discovery. Knowing a protein's shape helps scientists understand disease and design drugs. Second, it underpins the biotech industry. If a correctly built chain folds itself, then proteins can be made from genetic instructions or by chemical synthesis. When bacteria make a medicine protein as tangled clumps, producers dissolve and refold it, much as Anfinsen did in his test tubes. Third, a 1968 paper from his lab, led by two of his postdocs, made affinity chromatography a practical way to fish one molecule out of a soup using bait molecules fixed to beads. A version of it has long been the main purification step for antibody medicines. He also helped purify interferon in the 1970s, trained hundreds of young doctors as researchers at NIH, helped build a stream of scientific exchange between NIH and Israel's Weizmann Institute, and spent years pressing governments to free persecuted scientists.

  • The 2024 Nobel Prize in Chemistry honored AI prediction of protein shapes, a challenge the Nobel committee traces to Anfinsen's finding that sequence governs structure. By October 2024, AlphaFold2 had over two million users in 190 countries.[30]
  • His memoirist, a former NIH colleague, says the thermodynamic hypothesis helped get biotechnology started, because it implied that proteins could be built from DNA instructions or by chemical synthesis and still fold correctly.[6]
  • A 1968 paper from his lab, with Pedro Cuatrecasas and Meir Wilchek, showed how affinity chromatography could purify enzymes. Protein A affinity chromatography has long been the workhorse for purifying commercial antibody drugs.[21],[24],[25]
  • In 1974 his lab used affinity chromatography to partially purify human interferon, then available only in tiny amounts. Interferon drugs, later made by gene cloning, treat hepatitis C, multiple sclerosis and some cancers.[6],[11],[22]
  • As NAS human rights chair (1981-89), he joined a mission to rescue twelve scientists in Argentina and lobbied Soviet leaders for refuseniks. In 1984 he and 54 other scientists offered to take Yelena Bonner's place so she could get medical care abroad.[12],[15],[16],[17],[18]
  • He sat on the Weizmann Institute's board for decades and signed a 1967 petition backing Israel. His widow said he started a flow of about 400 Weizmann scientists to NIH, many to his own lab.[7],[14],[19]

Impact in numbers

Anfinsen's main gift is an idea: a protein's sequence contains the instructions for its shape. That idea is now in every biology textbook, and it framed the 50-year effort that ended with AI structure prediction, honored by the 2024 Nobel Prize. It also underlies how industry makes protein medicines from genes and refolds them when they come out tangled. We count two small, low-confidence shares of measured outcomes: 0.5% of cumulative sales of genetically engineered non-antibody protein medicines, and 0.2% of antibody-medicine sales, for his lab's role in launching affinity chromatography. Sales measure spending, not health gained. We make no claim for AlphaFold, protein design, interferon, his training of hundreds of young physician-scientists, or his defense of persecuted colleagues, because no honest number exists for them.

Fundamental scienceHealthEconomyHuman rights

Each number is the laureate’s credited share of a real-world outcome, cumulative to 2025. The whole outcome, the share of credit, and the reasoning are shown so you can check the arithmetic. Outcomes shared with other laureates are counted once on the impact page.

  • Low confidenceRippleModeledEconomy

    Cumulative global sales of genetically engineered non-antibody protein medicines (a proxy for economic activity)

    $7.5–10

    billion in economic value, credited share

    That is 0.5% of $1.5–2 trillion in economic value since 1982.

    How this number was built

    Same outcome and range as the Berg, Kornberg, Lederberg, Jacob, Luria and Lwoff profiles: world sales of recombinant non-antibody protein medicines since Humulin (1982). 2013 antibody sales (~$75B) were about half of biopharma (Ecker 2015); in 2021 non-antibody originator proteins sold $53.6B and biosimilars $11.1B (Walsh 2022). Low: quadratic ramp to $75B over 1982-2013 ($0.81T) + fall to $53.6B in 2014-21 ($0.50T) + flat 2022-25 ($0.21T) = ~$1.5T. High: linear ramp ($1.2T) + same later years + half of biosimilars = ~$2.0T. Sales, not net benefit. Share 0.005 (~$8-10B): his hypothesis told industry that a correctly made chain folds, or can be refolded from bacterial clumps, into active protein (Schechter; Yamaguchi 2014), but cloning, expression and manufacturing were others' work.[6],[26],[27],[28]

    Sources: Nature Biotechnology (via PubMed Central); mAbs (via PubMed Central); National Academy of Sciences; Biomolecules (via PubMed Central)

  • Low confidenceRippleModeledEconomy

    Cumulative global sales of monoclonal antibody medicines (a proxy for economic activity)

    $4–5.2

    billion in economic value, credited share

    That is 0.2% of $2–2.6 trillion in economic value since 1986.

    How this number was built

    Range matches the Milstein profile. Sales ~$39B (2008), ~$75B (2013) (Ecker 2015), $115.2B (2018, Lu 2020), $217B (2021, Walsh 2022); linear interpolation gives ~$1.39T for 2008-21. Low: add 2022-25 flat at $217B ($0.87T), ignore pre-2008, cut 10% for Fc-fusion drugs: (1.39+0.87) x 0.9 = ~$2.0T. High: add ~$0.18T for 1998-2007 and 8% yearly growth in 2022-25 (~$1.06T): ~$2.6T. Nominal dollars; sales, not health gained. Share 0.002 (~$4-5B): Protein A affinity chromatography has long been the workhorse capture step in commercial antibody purification (Liu 2010). Anfinsen was senior author of the 1968 paper that introduced affinity chromatography, but the Wolf Prize credits the concept to Cuatrecasas and Wilchek, an earlier affinity method existed (Campbell 1951), and Protein A resins came from others.[10],[21],[24],[25],[27],[28],[29]

    Sources: mAbs (via PubMed Central); Journal of Biomedical Science (via PubMed Central); Nature Biotechnology (via PubMed Central); mAbs (via PubMed Central); Proceedings of the National Academy of Sciences (via PubMed Central); Wolf Foundation; National Library of Medicine, Profiles in Science

The double edge

We found no documented harm from Anfinsen's research. The caveats are scientific. Many proteins inside cells need helper proteins, called chaperones, to fold properly, and their discovery led some scientists to question how far his rule reaches. His NAS memoirist argues the rule still holds for a protein's final shape, and notes that Anfinsen's own lab found one of the first folding helpers. Interferon, which he hoped would become a powerful cancer and antiviral drug, did not live up to early hopes that it would be a wonder drug, and gene cloning overtook his protein-chemistry approach to it. Around 1988 to 1990 he was also among scientists who opposed the proposed Human Genome Project, arguing that sequencing the whole genome would waste effort because most of it was filler.

  • Minor

    Limits of the folding rule

    Later research found chaperones, proteins that help other proteins fold inside cells. Their discovery led some scientists to doubt whether his hypothesis mattered much, or was even right. His NAS memoirist replies that the hypothesis concerns the final, most stable shape, not the route taken to reach it.[6]

  • Minor

    Opposed the Human Genome Project

    In 1988 he joined a small group of scientists who opposed the planned Human Genome Project with petitions and at international meetings. In 1990 he argued that most of the genome, about 95% by his count, was filler, so reading all of it would waste effort.[12]

Against the odds

Anfinsen's own path involved no antisemitic barriers. He grew up in a Norwegian-American family in the Philadelphia area, went to Swarthmore College on a scholarship, and rose quickly at Harvard and the National Institutes of Health. He became Jewish by choice in 1979, seven years after his Nobel Prize. The hardships in his story belong mostly to others, and to the way he answered them. World War II cut short his first research year in Copenhagen in 1940. That spring Germany invaded Norway, his parents' homeland. About 2,100 Jews lived there; roughly 770 were deported, and only about 34 survived. His widow later said the family of his Jewish maternal grandmother disappeared after the invasion, though we found no record that confirms it. Anfinsen spent much of his fame on people in danger. In May 1967 he signed a petition backing Israel as war approached, and his widow recalled him rushing to secure skin for grafts for wounded Israeli soldiers during the Six-Day War. He chaired the National Academy of Sciences human rights committee from 1981 to 1989, joined a mission to Argentina to rescue persecuted scientists, and wrote to Soviet leaders for refuseniks such as the molecular biologist Vladimir Raiz, who had applied to emigrate to Israel in 1973 and was let out only in 1990.

  • 1940

    War

    World War II spread to Scandinavia in 1940 and cut short his fellowship at the Carlsberg Laboratory in Copenhagen, sending him back to the United States.[6],[7]

  • 1940

    Other

    His widow said the family of his Jewish maternal grandmother disappeared after the Nazis invaded Norway in 1940. About 770 Jews were deported from Norway, and only about 34 survived. We found no independent record of what happened to his relatives.[14],[31]

  • 1981

    Other

    He retired from NIH and moved to Israel to be chief scientist of a new Weizmann Institute company. About two weeks after he arrived, its American backer, E. F. Hutton, pulled out, leaving him without work for about a year.[7],[13]

Jewish background

Converted to JudaismReligiously observant

Anfinsen was not born Jewish. His parents were Norwegian immigrants whom his widow described as Bible-reading Lutherans, and he was agnostic for decades. His ties to Israel began in 1956, when the Israeli chemist Michael Sela joined his lab, and he sat on the Weizmann Institute's board from 1962. In 1979, when he married Libby Shulman Ely, he formally converted to Orthodox Judaism, took the Hebrew name Chaim, and from then on kept many Jewish customs. In 1987 he wrote that his feelings about religion still reflected fifty years of agnosticism, but that Judaism's history and practice interested him deeply. His widow said his maternal grandmother was Jewish; we found no other source.[6],[7],[13],[14]

Key dates

  1. March 26, 1916

    Born in Monessen, Pennsylvania, the son of Norwegian immigrants; his father was an engineer.[1],[6],[7]

  2. 1937

    Graduates in chemistry from Swarthmore College, where he played on the football team.[2],[7],[8]

  3. 1939

    After a master's degree at the University of Pennsylvania, begins a fellowship at the Carlsberg Laboratory in Copenhagen; the war sends him home in 1940.[2],[6],[8]

  4. 1943

    Earns a PhD in biochemistry at Harvard Medical School and joins wartime malaria research.[2],[6]

  5. 1950

    Moves to the National Institutes of Health in Bethesda to head a laboratory at the National Heart Institute.[2],[7],[8]

  6. 1956

    The Israeli chemist Michael Sela joins his lab, starting Anfinsen's lifelong ties to the Weizmann Institute of Science.[6],[13]

  7. 1961

    His team shows that unraveled ribonuclease refolds by itself into its active form: the sequence alone decides the shape.[1],[6],[20]

  8. 1968

    Publishes, with Pedro Cuatrecasas and Meir Wilchek, a landmark paper showing how affinity chromatography can purify enzymes.[21],[24]

  9. 1972

    Receives half of the Nobel Prize in Chemistry; Stanford Moore and William H. Stein share the other half. He gives his banquet thanks in a mix of Scandinavian languages.[1],[4],[5]

  10. 1974

    His lab uses affinity chromatography to partially purify human interferon, then scarce; by 1980 it reads the first stretch of its amino acid chain.[11],[22],[23]

  11. 1979

    Marries Libby Shulman Ely and formally converts to Orthodox Judaism.[6],[7],[13]

  12. 1981

    Leaves NIH for a job in Israel that collapses within weeks; becomes chair of the National Academy of Sciences human rights committee.[7],[12],[13]

  13. 1982

    Joins Johns Hopkins University, where he later studies enzymes from microbes that thrive in extreme heat.[7],[15]

  14. May 14, 1995

    Dies of a heart attack in Randallstown, Maryland, aged 79, still running a research project.[1],[7],[15]

Sources

  1. 1.Christian Anfinsen - Facts · NobelPrize.org (Nobel Prize Outreach)
  2. 2.Christian Anfinsen - Biographical (from Les Prix Nobel 1972, with a 2003 addendum provided by Libby Anfinsen) · NobelPrize.org (Nobel Foundation), 1972
  3. 3.Studies on the Principles that Govern the Folding of Protein Chains (Nobel Lecture, 11 December 1972) · NobelPrize.org (Nobel Foundation), 1972
  4. 4.Press release: The Nobel Prize in Chemistry 1972 · NobelPrize.org (Royal Swedish Academy of Sciences), 1972
  5. 5.Christian Anfinsen - Banquet speech, Stockholm, 10 December 1972 · NobelPrize.org (Nobel Foundation), 1972
  6. 6.Christian B. Anfinsen 1916-1995: A Biographical Memoir (Alan N. Schechter) · National Academy of Sciences, 2015
  7. 7.The Christian B. Anfinsen Papers: Biographical Overview · National Library of Medicine, Profiles in Science
  8. 8.The Christian B. Anfinsen Papers: Brief Chronology · National Library of Medicine, Profiles in Science
  9. 9.The Christian B. Anfinsen Papers: Protein Folding and the Thermodynamic Hypothesis, 1950-1962 · National Library of Medicine, Profiles in Science
  10. 10.The Christian B. Anfinsen Papers: Molecular Engineering and Affinity Chromatography, 1959-1972 · National Library of Medicine, Profiles in Science
  11. 11.The Christian B. Anfinsen Papers: Interferon and Thermophilic Bacteria, 1973-1995 · National Library of Medicine, Profiles in Science
  12. 12.The Christian B. Anfinsen Papers: Humanitarian and Political Activism, 1967-1994 · National Library of Medicine, Profiles in Science
  13. 13.Autobiographical profile of Christian B. Anfinsen (50th Reunion Yearbook, Swarthmore College Class of 1937) · National Library of Medicine, Profiles in Science (Christian B. Anfinsen Papers), 1987
  14. 14.Memorial speech for Christian B. Anfinsen at Memorial Garden Dedication, Weizmann Institute (Libby Anfinsen, 16 November 1995) · National Library of Medicine, Profiles in Science (Christian B. Anfinsen Papers), 1995
  15. 15.Obituary: Christian Anfinsen (Evangelos N. Moudrianakis) · The Independent, 1995
  16. 16.Letter from Christian B. Anfinsen to Rudolph Kuznetsov, Andrei A. Gromyko, Edward Shevardnadze, G. I. Marchuk (re: Vladimir Raiz), 31 March 1988 · National Library of Medicine, Profiles in Science (Christian B. Anfinsen Papers), 1988
  17. 17.Letter from Committee of Concerned Scientists, Inc. (re: Vladimir Raiz), 28 March 1988 · National Library of Medicine, Profiles in Science (Christian B. Anfinsen Papers), 1988
  18. 18.Letter from Christian B. Anfinsen to Mikhail S. Gorbachev (re: Igor Uspensky), 19 August 1987 · National Library of Medicine, Profiles in Science (Christian B. Anfinsen Papers), 1987
  19. 19.Petition condemning the Arab blockade of the Straits of Tiran and the Gulf of Aqaba (Ad Hoc Committee of American Professors, May 1967) · National Library of Medicine, Profiles in Science (Christian B. Anfinsen Papers), 1967
  20. 20.The kinetics of formation of native ribonuclease during oxidation of the reduced polypeptide chain (Anfinsen CB, Haber E, Sela M, White FH Jr), PNAS 47:1309-1314 · Proceedings of the National Academy of Sciences (via PubMed Central), 1961
  21. 21.Selective enzyme purification by affinity chromatography (Cuatrecasas P, Wilchek M, Anfinsen CB), PNAS 61:636-643 · Proceedings of the National Academy of Sciences (via PubMed Central), 1968
  22. 22.Partial purification of human interferon by affinity chromatography (Anfinsen CB, Bose S, Corley L, Gurari-Rotman D), PNAS 71:3139-3142 · Proceedings of the National Academy of Sciences (via PubMed Central), 1974
  23. 23.Amino terminal sequence of the major component of human lymphoblastoid interferon (Zoon KC, Smith ME, Bridgen PJ, Anfinsen CB, Hunkapiller MW, Hood LE), Science 207:527-528 · PubMed (National Library of Medicine), 1980
  24. 24.Meir Wilchek - Wolf Prize Laureate in Medicine 1987 (shared with Pedro Cuatrecasas) · Wolf Foundation, 1987
  25. 25.Recovery and purification process development for monoclonal antibody production (Liu HF, Ma J, Winter C, Bayer R), mAbs 2(5):480-499 · mAbs (via PubMed Central), 2010
  26. 26.Refolding techniques for recovering biologically active recombinant proteins from inclusion bodies (Yamaguchi H, Miyazaki M), Biomolecules 4(1):235-251 · Biomolecules (via PubMed Central), 2014
  27. 27.Biopharmaceutical benchmarks 2022 (Walsh G, Walsh E), Nature Biotechnology 40:1722-1760 · Nature Biotechnology (via PubMed Central), 2022
  28. 28.The therapeutic monoclonal antibody market (Ecker DM, Jones SD, Levine HL), mAbs 7(1):9-14 · mAbs (via PubMed Central), 2015
  29. 29.Development of therapeutic antibodies for the treatment of diseases (Lu RM et al.), Journal of Biomedical Science 27:1 · Journal of Biomedical Science (via PubMed Central), 2020
  30. 30.Popular information: The Nobel Prize in Chemistry 2024 (They cracked the code for proteins' amazing structures) · NobelPrize.org (Royal Swedish Academy of Sciences), 2024
  31. 31.Norway (Holocaust Encyclopedia) · United States Holocaust Memorial Museum, 2021

Fact-checked on September 24, 2026 by a separate AI fact-checking pass that re-opened the sources, with 6 corrections made. How we check

Suggest a correction